ide849
ide849: sourced relationships with 1 company · 1 clinical trial tracked.
ide849 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ide849 to IDYA; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ide849 → IDYA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer
Primary endpoint: Part 1A: Safety and Tolerability of IDE849 (Monotherapy)
Interventionalopen262 targetStarted 2025-10Completion 2029-0713 sites · United StatesIDEAYA Biosciences
Frequently asked questions
Which companies have sourced relationships with ide849?
ide849 has dated SEC/FDA relationship records for IDEAYA Biosciences, Inc..
How many clinical trials involve ide849?
BioSniper tracks 1 clinical trial involving ide849.